Gastric Ulcers Market Report 2026

The gastric ulcers market size has grown strongly in recent years. It will grow from $4.53 billion in 2025 to $4.78 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to prevalence of h pylori infection, widespread use of antacids, availability of antibiotics, hospital-based GI treatments, adoption of endoscopic diagnosis.

The gastric ulcers market size is expected to see steady growth in the next few years. It will grow to $5.78 billion in 2030 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to development of advanced acid-suppression drugs, demand for long-term ulcer management, growth in outpatient care, improved diagnostic technologies, increased lifestyle-related disorders. Major trends in the forecast period include increased use of proton pump inhibitors, rising focus on helicobacter pylori eradication, growth in combination drug therapies, expansion of non-invasive diagnostic methods, increased awareness of gastrointestinal disorders.

The growing geriatric population is expected to drive the expansion of the gastric ulcers market in the coming years. The geriatric population generally includes individuals aged 65 years and above and is associated with age-related health challenges. Growth in this population is largely attributed to improvements in healthcare that have increased life expectancy, along with declining birth rates across many regions worldwide. Gastric ulcers are more prevalent among older adults due to factors such as higher usage of nonsteroidal anti-inflammatory drugs (NSAIDs) and reduced gastric mucosal protection, which increase the risk of complications. For example, in January 2024, the Population Reference Bureau (PRB), a US-based private nonprofit organization, reported that the number of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, reflecting a 47% rise. In addition, this age group’s share of the total population is expected to grow from 17% to 23%, underscoring a pronounced aging trend in the U.S. population. Consequently, the expanding geriatric population is fueling growth in the gastric ulcers market.

Leading companies in the gastric ulcer market are concentrating on the development of innovative drug formulations to improve therapeutic effectiveness and minimize adverse effects. New drug formulations involve advanced combinations of active ingredients, delivery mechanisms, or dosage forms designed to enhance efficacy, safety, and patient adherence. For instance, in June 2024, Akums Drugs and Pharmaceuticals Ltd., an India-based pharmaceutical manufacturing company, introduced Rabeprazole + Levosulpiride SR capsules to offer improved management of conditions such as gastroesophageal reflux disease (GERD) and other gastrointestinal tract disorders. This formulation combines a proton pump inhibitor with a prokinetic agent, effectively addressing gastric ulcers and related gastrointestinal conditions by reducing acid secretion while improving gastric motility, thereby delivering broader symptom relief, including heartburn and indigestion.

In July 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical company focused on branded and generic medicines, entered into a partnership with Takeda Pharmaceutical Company for Vonoprazan. Through this collaboration, Dr. Reddy’s aims to commercialize Takeda’s next-generation potassium-competitive acid blocker in India, strengthening its gastrointestinal treatment portfolio. Vonoprazan is indicated for acid peptic disorders, including gastric ulcer, duodenal ulcer, and Helicobacter pylori-associated diseases, and is an orally active acid-suppressing therapy developed by Takeda.

Major companies operating in the gastric ulcers market are Pfizer Inc., Merck & Co Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Co. Ltd, Boehringer Ingelheim, Viatris Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd, Cadila Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Yuhan Corporation, Daewoong Pharmaceutical Co. Ltd, Cadila Healthcare Ltd, Novitium Pharma LLC.

North America was the largest region in the gastric ulcers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric ulcers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastric ulcers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gastric ulcers market by increasing costs of imported pharmaceuticals, diagnostic reagents, and medical equipment. Hospital and retail pharmacies are most affected due to reliance on imported drugs. These tariffs raise treatment costs by increasing procurement expenses for proton pump inhibitors, antibiotics, and diagnostic consumables, potentially affecting patient affordability and long-term disease management. However, they promote domestic drug production, encouraging local manufacturing of ulcer therapeutics and reducing dependence on imported medications.

The gastric ulcers market research report is one of a series of new reports that provides gastric ulcers market statistics, including gastric ulcers industry global market size, regional shares, competitors with a gastric ulcers market share, detailed gastric ulcers market segments, market trends and opportunities, and any further data you may need to thrive in the gastric ulcers industry. This gastric ulcers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gastric ulcers, also known as peptic ulcers, are open sores that develop on the inner lining of the stomach as a result of the corrosive effects of stomach acid. They commonly cause burning abdominal pain, indigestion, and discomfort. Gastric ulcers typically arise from an imbalance between stomach acid, the enzyme pepsin, and the protective mucosal barrier of the stomach and duodenum.

The main drug classes used for treating gastric ulcers include proton pump inhibitors (PPIs), H2 antagonists, antacids, antibiotics, cytoprotective agents, and others. Proton pump inhibitors are a class of medications that decrease stomach acid production by blocking the proton pump enzyme in gastric cells. Gastric ulcers can be diagnosed using stool tests, endoscopy, imaging tests, computed tomography (CT) scans, X-rays, blood tests, and others, and treatments are administered through various routes such as oral, parenteral, and others. Distribution channels primarily include hospital pharmacies, retail pharmacies, online pharmacies, and others, and these treatments are used by a range of end-users, including hospitals, specialty clinics, homecare settings, and others.

The gastric ulcers market consists of revenues earned by entities through barium swallow, H. pylori testing, and biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastric ulcers market also includes sales of amoxicillin, clarithromycin, metronidazole, omeprazole, and lansoprazole. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.